AU2015292582A1 - Collagen IV replacement - Google Patents

Collagen IV replacement Download PDF

Info

Publication number
AU2015292582A1
AU2015292582A1 AU2015292582A AU2015292582A AU2015292582A1 AU 2015292582 A1 AU2015292582 A1 AU 2015292582A1 AU 2015292582 A AU2015292582 A AU 2015292582A AU 2015292582 A AU2015292582 A AU 2015292582A AU 2015292582 A1 AU2015292582 A1 AU 2015292582A1
Authority
AU
Australia
Prior art keywords
collagen
chain
protein
chimeric
alport syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015292582A
Other languages
English (en)
Inventor
Thomas Michael Barnes
Bradley Lowell HODGES
Walter Eugene KOWTONIUK
Philip Raymond REILLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goldfinch Bio Inc
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of AU2015292582A1 publication Critical patent/AU2015292582A1/en
Assigned to GOLDFINCH BIO, INC. reassignment GOLDFINCH BIO, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: GOLDFINCH BIOPHARMA, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2015292582A 2014-07-25 2015-07-23 Collagen IV replacement Abandoned AU2015292582A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462029135P 2014-07-25 2014-07-25
US62/029,135 2014-07-25
US201462072490P 2014-10-30 2014-10-30
US62/072,490 2014-10-30
US201562128729P 2015-03-05 2015-03-05
US62/128,729 2015-03-05
PCT/US2015/041712 WO2016014781A1 (en) 2014-07-25 2015-07-23 Collagen iv replacement

Publications (1)

Publication Number Publication Date
AU2015292582A1 true AU2015292582A1 (en) 2017-02-02

Family

ID=55163752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015292582A Abandoned AU2015292582A1 (en) 2014-07-25 2015-07-23 Collagen IV replacement

Country Status (6)

Country Link
US (1) US20180207240A1 (https=)
EP (1) EP3171889A4 (https=)
JP (1) JP2017532365A (https=)
AU (1) AU2015292582A1 (https=)
CA (1) CA2955481A1 (https=)
WO (1) WO2016014781A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL264725B2 (en) * 2016-08-11 2023-03-01 Sulfilatec Inc Preparations and methods for treating the disease
GB201717301D0 (en) * 2017-10-20 2017-12-06 Nordic Bioscience As Type xvi collagen assay
JP2021532191A (ja) * 2018-07-25 2021-11-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルポート症候群の治療に使用するためのエンパグリフロジン
EP4029514A4 (en) * 2019-09-11 2023-10-11 National University Corporation Kumamoto University Drug for curative therapy of intractable hereditary renal alport syndrome
US12164185B2 (en) * 2020-02-14 2024-12-10 Tdk Corporation Optical modulation element
GB202003618D0 (en) * 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
EP4255427B1 (en) * 2020-12-03 2024-11-06 Delta 4 GmbH Clopidogrel for use in the treatment of focal segmental glomerulosclerosis (fsgs)
CN114149502A (zh) * 2021-12-23 2022-03-08 杭州百凌生物科技有限公司 一种四型胶原蛋白ɑ3的抗体、检测试剂盒及其应用
CN115960211B (zh) * 2022-12-23 2023-11-21 江苏创健医疗科技股份有限公司 一种重组人源ⅵ型胶原蛋白及其制备方法和应用
WO2025193938A1 (en) * 2024-03-13 2025-09-18 Oregon Health & Science University Delivery of type iv collagen alpha chain using a split intein dual aav vector
CN119286901B (zh) * 2024-11-21 2025-09-09 西安巨子生物基因技术股份有限公司 一种重组iv型胶原蛋白及其制备方法和应用
CN120731923B (zh) * 2025-09-05 2025-11-04 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) 一种Alport综合征小鼠NMD逃逸模型的构建方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
PT1064018E (pt) * 1998-03-27 2004-12-31 Univ Kansas Medical Center Utilizacao de dominios isolados de colagenio de tipo iv para modificar interaccoes celulares e teciduais
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2451942A1 (en) * 2001-07-27 2003-02-13 Munirathinam Sundaramoorthy Crystallized structure of type iv collagen nc1 domain hexamer
US7183383B2 (en) * 2002-03-20 2007-02-27 The University Of Arkansas For Medical Sciences Uses of collagen IV
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US20130116412A1 (en) * 2010-04-02 2013-05-09 Daniel M. Pinkas Production of Post-Translationally Hydroxylated Recombinant Proteins in Bacteria
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US20180055913A1 (en) * 2014-07-29 2018-03-01 Vanderbilt University Recombinant collagen iv surrogates and uses thereof

Also Published As

Publication number Publication date
CA2955481A1 (en) 2016-01-28
WO2016014781A1 (en) 2016-01-28
EP3171889A1 (en) 2017-05-31
EP3171889A4 (en) 2018-03-14
US20180207240A1 (en) 2018-07-26
JP2017532365A (ja) 2017-11-02

Similar Documents

Publication Publication Date Title
US20180207240A1 (en) Collagen iv replacement
US20220313830A1 (en) Heparin-peptide bioconjugates and uses thereof
Sand et al. Type IV collagen
JP5917437B2 (ja) Ａｄｐリボシルトランスフェラーゼ融合バリアントタンパク質
AU4004799A (en) Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
US11529424B2 (en) Synthetic bioconjugates
US20260041786A1 (en) Mineral coated microparticles for sustained delivery of biologically active molecules
WO2018107687A1 (zh) 一种预防和治疗高脂血症的方法
CA3117723A1 (en) Methods of cellular reprogramming
HK1257236A1 (zh) 预防和治疗高脂血症的药物及其用途
NZ508317A (en) Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
AU2013202269A1 (en) Compositions and methods for the treatment of fibrosis and fibrotic diseases
US7498299B2 (en) Procollagen (III) propeptides and related substances for treating fibrotic diseases
US20030220253A1 (en) Inhibitors for use in hemostasis
CN108210908A (zh) 预防和治疗药物性肾损伤的药物及其用途
EP3185891B1 (de) Rekombinante fusionsproteine zur vorbeugung oder behandlung von adhäsionen bei geweben oder organen
CN119954893A (zh) 一种新型pace4抑制剂及其在抗骨关节炎中的应用
WO2019219923A1 (en) Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
MXPA00011409A (en) Use of alpha 1 beta 1 integrin receptor inhibitors and tgf-bgr;1 inhibitors in the treatment of kidney disease
IL139687A (en) Use of ß11α integrin receptor inhibitors and TGF β1 inhibitors for the preparation of medicinal preparations for the treatment of kidney disease

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: GOLDFINCH BIO, INC.

Free format text: FORMER NAME(S): GOLDFINCH BIOPHARMA, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application